[1]
|
Zipursky, A. (2003) Transient Leukaemia—A Benign Form of Leukaemia in Newborn Infants with Trisomy 21. British Journal of Haematology, 120, 930-938.
https://doi.org/10.1046/j.1365-2141.2003.04229.x
|
[2]
|
Lange, B. (2000) The Management of Neoplastic Disorders of Haematopoiesis in Children with Down’s Syndrome. British Journal of Haematology, 110, 512-524.
https://doi.org/10.1046/j.1365-2141.2000.02027.x
|
[3]
|
Shiozawa, Y., Fujita, H., Fujimura, J., Suzuki, K., Sato, H., Saito, M., Shimizu, T. and Yamashiro, Y. (2004) A Fetal Case of Transient Abnormal Myelopoiesis with Severe Liver Failure in Down Syndrome: Prognostic Value of Serum Markers. Pediatric Hematology and Oncology, 21, 273-278.
https://doi.org/10.1080/08880010490277088
|
[4]
|
Hoskote, A., Chessells, J. and Pierce, C. (2002) Transient Abnormal Myelopoiesis (TAM) Causing Multiple Organ Failure. Intensive Care Medicine, 28, 758-762.
https://doi.org/10.1007/s00134-002-1305-7
|
[5]
|
Kiso, Y., Ogasawara, S., Hirota, K., Watanabe, N., Oshima, Y., Konno, C. and Hikiko, H. (1984) Antihepatotoxic Principles of Artemisia Capillaries Buds 1. Planta Medica, 50, 81-85. https://doi.org/10.1055/s-2007-969627
|
[6]
|
Iinuma, Y., Kubota, M., Yagi, M., Kanada, S., Yamazaki, S. and Kinoshita, Y. (2003) Effects of the Herbal Medicine Inchinko-to on Liver Function in Postoperative Patients with Biliary Atresia—A Pilot Study. Journal of Pediatric Surgery, 38, 1607-1611. https://doi.org/10.1016/S0022-3468(03)00570-0
|
[7]
|
Tamura, T., Kobayashi, H., Yamataka, A., Lane, G.J., Koga, H. and Miyano, T. (2007) Inchin-ko-to Prevents Medium-Term Liver Fibrosis in Postoperative Biliary Atresia Patients. Pediatric Surgery International, 23, 343-347.
https://doi.org/10.1007/s00383-007-1887-9
|
[8]
|
Kaiho, T., Tsuchiya, S., Yanagisawa, S., Takeuchi, O., Togawa, A., Okamoto, R., Saigusa, N. and Miyazaki, M. (2008) Effect of the Herbal Medicine Inchin-Ko-To for Serum Bilirubin in Hepatectomized Patients. Hepatogastroenterology, 55, 150-154.
|
[9]
|
Takahashi, Y., Soejima, Y., Kumagai, A., Watanabe, M., Uozaki, H. and Fukusato, T. (2014) Japanese Herbal Medicines Shosaikoto, Inchinkoto, and Juzentaihoto Inhibit High-Fat Diet-Induced Nonalcoholic Steatohepatitis in db/db Mice. Pathology International, 64, 490-498. https://doi.org/10.1111/pin.12199
|
[10]
|
Yamamoto, M., Ogawa, K., Morita, M., Fukuda, K. and Komatsu, Y. (1996) The Herbal Medicine Inchin-ko-to Inhibits Liver Cell Apoptosis Induced by Transforming Growth Factor Beta 1. Hepatology, 23, 552-559.
|
[11]
|
Yamashiki, M., Mase, A., Arai, I., Huang, X.X., Nobori, T., Nishimura, A., Sakaguchi, S. and Inoue, K. (2000) Effects of the Japanese Herbal Medicine “Inchinko-to” (TJ-135) on Concanavalin A-Induced Hepatitis in Mice. Clinical Science (Lond), 99, 421-431. https://doi.org/10.1042/cs0990421
|
[12]
|
Matsuura, T., Kaibori, M., Araki, Y., Matsumiya, M., Yamamoto, Y., Ikeya, Y., Nishizawa, M. and Okumura, K.A.H. (2012) Japanese Herbal Medicine, Inchinkoto, Inhibits Inducible Nitric Oxide Synthase Induction in Interleukin-1β-Stimulated Hepatocytes. Hepatology Research, 42, 76-90.
https://doi.org/10.1111/j.1872-034X.2011.00891.x
|
[13]
|
Inao, M., Mochida, S., Matsui, A., Eguchi, Y., Yulutuz, Y., Wang, Y., Naiki, K., Kakinuma, T., Fujimori, K., Nagoshi, S. and Fujiwara, K. (2004) Japanese Herbal Medicine Inchin-ko-to as a Therapeutic Drug for Liver Fibrosis. Journal of Hepatology, 41, 584-591. https://doi.org/10.1016/j.jhep.2004.06.033
|
[14]
|
Schuppan, D. and Afdhal, N.H. (2008) Liver Cirrhosis. Lancet, 371, 838-851.
https://doi.org/10.1016/S0140-6736(08)60383-9
|
[15]
|
Kuroiwa, Y., Suzuki, N., Yamamoto, M., Hatakeyama, N., Hori, T. and Mizue, N. (2005) Prognostic Value of Serum Markers for Liver Fibrosis in Transient Abnormal Myelopoiesis (TAM). Rinsho Ketsueki, 46, 1179-1186.
|
[16]
|
Mansini, A.P., Rubio, P.L., Rossi, J.G., Gallego, M.S., Medina, A., Zubizarreta, P.A., Felice, M.S. and Alonso, C.N. (2013) Mutation Characterization in the GATA-1 Gene in Patients with Down’s Syndrome Diagnosed with Transient Abnormal Myelopoiesis or Acute Megakaryoblastic Leukemia. Archivos Argentinos de Pediatria, 111, 532-536.
|
[17]
|
Roy, A., Roberts, I., Norton, A. and Vyas, P. (2009) Acute Megakaryoblastic Leukemia (AMKL) and Transient Myeloproliferative Disorder (TMD) in Down Syndrome: A Multi-Step Model of Myeloid Leukaemogenesis. British Journal of Haematology, 147, 3-12. https://doi.org/10.1111/j.1365-2141.2009.07789.x
|
[18]
|
Ahmed, M., Sternberg, A., Hall, G., Thomas, A., Smith, O., O’Marcaigh, A., Wynn, R., Stevens, R., Addison, M., King, D., Stewart, B., Gibson, B., Roberts, I. and Vyas, P. (2004) Natural History of GATA1 Mutations in Down Syndrome. Blood, 103, 2480-2489. https://doi.org/10.1182/blood-2003-10-3383
|
[19]
|
Birger, Y., Goldberg, L., Chlon, T.M., Goldenson, B., Muler, I., Schiby, G., Jacob-Hirsch, J., Rechavi, G., Crispino, J.D. and Izraeli, S. (2013) Perturbation of Fetal Hematopoiesis in a Mouse Model of Down Syndrome’s Transient Myeloproliferative Disorder. Blood, 122, 988-998. https://doi.org/10.1182/blood-2012-10-460998
|